In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...

Alexion wasn’t messing around when it set its goal for converting patients to brand-new Ultomiris, but so far, so good. The company appears to be on track to hit—perhaps even exceed—its lofty target.

Health regulators in Japan have given Alexion Pharmaceuticals Inc. the green light to market its new drug Ultomiris for a second rare blood disease. The drug, the company’s follow-up to its ...

Alexion Pharmaceuticals secured approval Friday from the Food and Drug Administration for a new drug called Ultomiris that will be used to treat an ultra-rare blood disease and ultimately replace the ...

- ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients receiving SOLIRIS ® (eculizumab) - BOSTON--(BUSINESS WIRE)--Alexion ...

Novartis has its eye on the market held by a pair of AstraZeneca's rare disease gems. The latest data showing that the Swiss drugmakers' iptacopan increases hemoglobin levels in a disease called ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already ...

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with ...

BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...

2Q20 total revenues of $1,444.6 million, a 20% increase over 2Q19 2Q20 GAAP diluted EPS of $(4.84); non-GAAP diluted EPS of $3.11 Achieved goal of establishing ULTOMIRIS ® (ravulizumab-cwvz) as new ...